571 related articles for article (PubMed ID: 7687976)
1. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Matsubara R
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo.
Matsubara S; Matsubara R; Kusumi I; Koyama T; Yamashita I
J Pharmacol Exp Ther; 1993 May; 265(2):498-508. PubMed ID: 7684443
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors.
Czyrak A; Jaros T; Moryl E; Maj J
Pharmacopsychiatry; 1993 Mar; 26(2):53-8. PubMed ID: 7690975
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
[TBL] [Abstract][Full Text] [Related]
5. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
[TBL] [Abstract][Full Text] [Related]
7. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
Herrick-Davis K; Grinde E; Teitler M
J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
[TBL] [Abstract][Full Text] [Related]
8. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
9. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
Stockmeier CA; DiCarlo JJ; Zhang Y; Thompson P; Meltzer HY
J Pharmacol Exp Ther; 1993 Sep; 266(3):1374-84. PubMed ID: 8103793
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes.
Czyrak A; Skuza G; Rogóz Z; Frankiewicz T; Maj J
Arzneimittelforschung; 1994 Feb; 44(2):113-8. PubMed ID: 7511901
[TBL] [Abstract][Full Text] [Related]
11. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.
Meltzer HY; Matsubara S; Lee JC
Psychopharmacol Bull; 1989; 25(3):390-2. PubMed ID: 2576319
[TBL] [Abstract][Full Text] [Related]
12. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
13. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain.
O'Dell SJ; La Hoste GJ; Widmark CB; Shapiro RM; Potkin SG; Marshall JF
Synapse; 1990; 6(2):146-53. PubMed ID: 2237777
[TBL] [Abstract][Full Text] [Related]
14. Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex.
Matsubara S; Meltzer HY
Life Sci; 1989; 45(15):1397-406. PubMed ID: 2571912
[TBL] [Abstract][Full Text] [Related]
15. The importance of serotonin-dopamine interactions in the action of clozapine.
Meltzer HY
Br J Psychiatry Suppl; 1992 May; (17):22-9. PubMed ID: 1358125
[TBL] [Abstract][Full Text] [Related]
16. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Schotte A; Janssen PF; Gommeren W; Luyten WH; Van Gompel P; Lesage AS; De Loore K; Leysen JE
Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
[TBL] [Abstract][Full Text] [Related]
17. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
18. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
Szczepanik AM; Brougham LR; Roehr JE; Conway PG; Ellis DB; Wilmot CA
J Pharmacol Exp Ther; 1996 Aug; 278(2):913-20. PubMed ID: 8768747
[TBL] [Abstract][Full Text] [Related]
20. In vivo occupation of dopamine D1, D2 and serotonin (5-HT)2A receptors by sertindole in the rat brain.
Takahashi Y; Kusumi I; Ishikane T; Matsubara S; Koyama T
J Psychiatry Neurosci; 1998 May; 23(3):157-62. PubMed ID: 9595889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
